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Abstract 
Concentration distributions for 183 drugs and metabolites frequently found in post-mortem (PM) 
femoral venous blood were statistically characterized based on an extensive database of 122 234 
autopsy cases investigated during an 18-year period in a centralized laboratory. The cases represented 
all causes of death, with fatal drug poisonings accounting for 8%. The proportion of males was 74% 
with median age 58 years compared with 26% females with median age 64 years. In 36% of these 
cases, blood alcohol concentration was higher than or equal to 0.2‰, the median being 1.6‰. The 
mean, median, and upper percentile (90th, 95th, 97.5th) drug concentrations were established, as the 
median PM concentrations give an idea of the ‘normal’ PM concentration level, and the upper 
percentile concentrations indicate possible overdose levels. A correspondence was found between 
subsets of the present and the previously published PM drug concentrations from another laboratory 
that used grouping of cases according to the cause of death. Our results add to the knowledge for 
evidence-based interpretation of drug-related deaths. 
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Introduction 
Organized post-mortem (PM) toxicology service provides legal protection for both individuals and 
society and has an increasing impact on welfare and health as drug use is becoming more prevalent. 
During the last decades there has been considerable progress in many facets of the discipline, 
including development of analytical methods, understanding of post-mortem changes, and 
interpretation of results.1 Current quality-assured analytical results and their evidence-based 
interpretation make medico-legal cause-of-death investigation more reliable and improve the quality 
of death certificates. As national mortality statistics are based on death certificates, the information 
obtained from high-quality death certificates will, in turn, help authorities and policymakers to 
recognize trends of drug misuse and abuse and carry out the necessary interventions, thus improving 
drug safety.2-4 
 
In cause-of-death investigation, clinical history, autopsy findings and the totality of laboratory results 
have to be interpreted together. PM concentrations of drugs and poisons play a major role in the 
interpretation, but it is important to realize that reference ranges for PM concentrations are only one 
of the crucial elements in the process. Laboratories usually possess in-house databases of varying size 
with data gathered from case work. In addition, published case notes or small case series, as well as 
compilations collected from literature sources are available,5 but these data are often heterogeneous 
in terms of the sampling site, the analytical methods used, and the number of cases involved. There 
may even be a bias of publishing mainly cases with exceptionally high concentrations. 
 
The fact that PM drug concentrations are not necessarily the same as those at the time of death, called 
the PM drug redistribution (PMR), was brought to attention by Prouty and Anderson in their two 
papers published in 1987 and 1990,6,7 as well as by Pounder and Jones in 1990,8 but similar 
observations had been made much earlier.9 Drug levels may vary according to the sampling site and 
the interval between death and specimen collection (PM interval). In optimal circumstances, a sample 
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of PM venous blood from a femoral vein is taken as soon as possible after death, as this procedure is 
considered to give results that are the least susceptible to PM change.10,11 
 
Systematic collection and evaluation of reference concentrations in PM femoral blood have been 
carried out by Swedish investigators,12 taking advantage of the relatively high PM toxicology rate 
and uniform procedures in the country. In this approach, the cases are subdivided into poisonings by 
one specific substance only (Group A), multi-substance poisonings (Group B), and PM controls 
comprising deaths not involving incapacitation by substances (Group C). Moreover, the results are 
compared with data based on therapeutic drug monitoring and data collected from driving under the 
influence cases. This approach produces extremely valuable results, but the information retrieval is 
rather slow and laborious due to manual, multi-reviewer, case-by-case evaluation. Moreover, the 
number of cases especially in Group A may remain low, consisting of only a few concentration entries 
or no entries at all. 
 
Another systematic approach that relies on a high PM toxicology rate is to utilize the PM 
concentrations that accumulate during case work without pre-selection for cause of death. This “all-
causes-of-death approach”, introduced by Jones and Holmgren,13 is more straightforward and prolific 
regarding the number of cases and drugs involved, omitting the tedious manual case grouping step. 
Also based on the Swedish material, these authors published concentration distributions of 25 drugs 
most frequently identified in PM femoral blood. 
 
Finland is another country with a high PM toxicology rate and a centralized laboratory investigation. 
According to the law, all sudden and unexpected deaths undergo a medico-legal investigation, 
initiated by the police and conducted by a forensic pathologist. Specific grounds for the investigation 
include an obvious or suspected accident, suicide, crime, poisoning, occupational disease or medical 
treatment. As a result, in nearly 20% of all deaths a medico-legal investigation is performed.  
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In our former paper, we followed the all-causes-of-death approach and published the PM median, 
mean, and upper percentile (90th, 95th, 97.5th) concentrations calculated for 129 drugs based on 57 
903 Finnish autopsy cases with PM toxicology executed.14 In the present study, our main objective 
was to make the results of the original study more complete by extending the range to cover 183 drugs 
and metabolites, based on an even larger amount of accumulated data as a basis for the PM 
concentrations. Another objective was to compare our results with those published by the Swedish 
investigators. 
 
 
Materials and methods 
Toxicological analysis 
The Finnish medico-legal system and the PM toxicology services were described in detail in our 
previous paper.14 Briefly, the concentration data were acquired from femoral venous blood taken at 
autopsy, the samples containing 1% NaF and stored at 4ºC prior to analysis. The blood samples were 
quantitatively monitored for about 200 drugs on a routine basis using three comprehensive methods. 
For acidic and neutral drugs, dual-column gas chromatography with nitrogen phosphorus detection 
(GC-NPD)15 was used until replaced in February 2007 by a method based on GC coupled with mass 
spectrometry (GC-MS).16 For benzodiazepines, a GC method with electron capture detection (GC-
ECD)17 was used until March 2010, after which a method based on GC and negative-ion chemical 
ionization MS (GC-NCIMS)18 was adopted for routine use. A dual-column GC-NPD method was 
used for basic drug screening19 until December 2014, when a method based on ultra-high-
performance liquid chromatography with a photodiode array detector and a corona charged aerosol 
detector (UHPLC-DAD-CAD) was put into operation.20 Digoxin was analysed with an 
immunological method using Siemens Immulite 1000 or 2000XPi analyzers. Lithium was analysed 
by inductively coupled plasma mass spectrometry (ICP-MS) until February 2014, followed by a 
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method based on an ion-selective electrode. Confirmation and additional determinations were carried 
out by GC-MS and LC-MS/MS for drugs not covered by the comprehensive quantitative monitoring 
methods described above. All the concentration results were obtained by using quality-controlled and 
mostly accredited methods that relied on calibration with appropriate reference standards. Along with 
the changes in the analytical methods, the lower limit of quantification (LOQ) changed for some 
compounds (Table 2). 
 
Data refining 
During the period between 1 January 2000 and 31 December 2017 the results from quantitative 
analyses of drugs in PM femoral venous blood from 122 234 autopsy cases were entered into the 
toxicology database (Table 1). From this material, those drugs that had been quantified at least 18 
times in PM blood were selected, and the median, mean, and upper percentile (90th, 95th, 97.5th) 
concentrations (mg/L) were calculated from the findings (Table 2). 
 
Comparison to literature reference concentrations 
In Table 2, a one point reference concentration value in living persons’ plasma (Cplasma) was given for 
each drug to enable instant comparison with the PM concentrations. In most cases, the Cplasma values 
represented the upper limit of plasma/serum concentrations (in general, trough at steady state) 
observed following therapeutically effective doses.21 
 
Comparison to the PM concentrations from the Swedish investigators’ studies22-26 was based on the 
following concentration percentile ratios obtained from the two databases (Swedish/Finnish): 
median/median, 90th percentile/median, 90th /90th percentile, and 90th /97.5th percentile. First, the 
concentration percentile ratios were calculated for individual drugs, and second, the medians of these 
ratios were calculated and presented in Table 3. 
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Results and discussion 
Table 1 shows demographics of the 122 234 autopsy cases from the 18-year study period for which 
a comprehensive PM drug analysis was completed. The number of autopsies, the mean age, and the 
mean blood alcohol concentration (BAC) in cases where it exceeds the LOQ of 0.2‰ (g/kg) are given 
separately for males and females. The number of accumulated autopsy cases forming the basis of the 
concentration data is about twice the size of that in our original study,14 while the concentration data 
presented in that study forms a part of the present data. The demographics of the cases are fairly 
similar between these two studies in terms of gender distribution, age, and proportion of alcohol-
positive cases. Males and females represented 74 and 26% of the subjects, respectively, and the 
median age was 58 and 64 years, respectively. The prevalence of alcohol-positive cases was 36% and 
the median BAC was 1.6‰. These figures showed little difference from the original study.14 
 
Table 2 shows the concentration distributions in PM femoral venous blood for the 183 drugs and 
metabolites most frequently found in autopsy cases in alphabetical order, comprising 221 780 
individual concentration entries. There is an increase of 54 substances relative to the original study. 
Indicated are the number of cases, the LOQ, the PM mean, median, and upper percentile (90th, 95th, 
97.5th) concentrations. As stated in the original study, the median PM concentrations are likely to give 
an idea of the ‘normal’ PM concentration range, and the upper percentile concentrations indicate 
possible overdose levels. This judgment is supported by the fact that the manner of death is natural 
in approximately 55% of all PM toxicology cases in Finland, and the proportion of fatal drug 
poisonings in the present material was on average 8%. However, this concept of normal and overdose 
levels cannot be applied to each drug in a mechanical manner. 
 
Table 2 also lists clinical Cplasma values to roughly illustrate how the median PM femoral blood drug 
concentrations relate to the therapeutic ranges reported mainly in an established data compilation by 
Schulz et al.21 Calculating the PM median/Cplasma ratio one can get an idea of the PM behavior for a 
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particular drug. Apart from the PMR, exceptionally high PM median/Cplasma ratio values may arise 
from a high intrinsic clinical blood/plasma ratio and/or a high volume of distribution, as exemplified 
by dextromethorphan and hydroxychloroquine, or from the high proportion of poisonings by a 
particular drug in the database, as exemplified by dextropropoxyphene and promazine. 
Correspondingly, exceptionally low values may arise from a low clinical blood/plasma ratio, as 
exemplified by aripiprazole, warfarin, and some benzodiazepines. Obviously, the representativeness 
of the Cplasma values plays a role in the relevance of the ratio. The association between the 
pharmacological characteristics remarked above and the PM concentration levels has been discussed 
in more detail in our previous study.14 
 
Table 2 shows the relative differences in the PM median concentrations between the present database 
and the original database. For 18 drugs, the median concentration in the present database was more 
than 10% higher, and for 38 drugs it was more than 10% lower than in the original database. The 
mean (median) difference in the PM median concentrations between the databases was -5% (0%), 
and the mean (median) difference in the absolute values was 13% (8%). These findings suggest that 
the PM median concentrations are largely reproducible over the course of time, though there were 
some exceptions concerning individual drugs. The reasons for a more prominent change include a 
relatively low or a much changed number of cases, changed clinical prescription practices or changed 
abuse patterns. While LOQ is an important factor relative to the statistical concentration distribution, 
the current changes in LOQ were generally associated with only minor effects on the results. 
 
Table 3 shows the comparison of selected concentration percentiles in PM femoral venous blood 
between the present study, involving all causes of death (N = 144 034), and the five Swedish studies 
(N = 9436), employing grouping according to the cause of death.22-26 A moderate correspondence 
was obtained between Swedish group C and our median concentration, both representing a ‘normal’ 
PM concentration. The median ratios of Swedish group C median to our median and Swedish group 
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C 90th percentile to our median were 0.6 and 1.7, respectively. For example, in case of the 
antipsychotic drug olanzapine, our median concentration was 0.20 mg/L, while the Swedish group C 
median and 90th percentile were 0.10 mg/L and 0.20 mg/L, respectively.25 A correspondence also 
existed between the Swedish group A and B 90th percentiles and our 97.5th percentile (ratios 1.2 and 
0.9, respectively), representing lethal concentrations for most substances. Similarly, as exemplified 
by olanzapine, our 97.5th percentile concentration was 2.4 mg/L, while the Swedish group A and B 
90th percentile concentrations were 2.71 mg/L and 0.90 mg/L, respectively.25 These comparisons 
illustrate how the PM concentration values between the subgroups of the two large databases may or 
may not match, giving additional grounds for interpretation. 
 
Drug metabolites may have similar (e.g. N-desmethylamitriptyline) or different (e.g. N-
desmethylclomipramine) pharmacodynamic properties than their respective parent compounds, or 
they may be pharmacologically inactive (e.g. N-desmethylcitalopram).27 For those drugs with similar 
properties, the sum of the concentrations of parent drug and active metabolite can be used for 
interpretation. Even non-active metabolites are important from a pharmacokinetic perspective, 
because the metabolite-to-parent drug ratio (MPR) can be used for differentiating between acute and 
chronic intake.23 MPR sometimes allows identification of abnormal metabolism caused by 
pharmacokinetic interactions or genetic abnormalities,28 especially when compared with established 
ratios from therapeutic drug monitoring.27 As has been pointed out earlier, the PM concentrations of 
drugs of abuse, such as parenterally administered strong opioids12,29,30 and stimulants,31 are of limited 
value in assessing the cause of death because individual tolerance, route of administration, and poly-
drug abuse are more important factors in these cases. However, MPR can be decisive in interpreting 
the role of drugs in abuser deaths.32 In this study, we were able to report the PM concentrations of a 
limited number of drug metabolites, but we acknowledge that a wider range of metabolites is needed. 
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Interest is currently focused on the quantification of drugs in PM materials other than blood, including 
bile, brain, liver, muscle, and vitreous humor.33-38 However, while these alternative materials show 
promising results with individual drugs or in specific circumstances, femoral venous blood still 
represents the most viable material for interpretative purposes in PM toxicology, with a more 
extensive range of reference concentrations published in the literature. 
 
Conclusions 
We have provided an extended list of drug concentration distributions in PM femoral venous blood, 
accumulated during an 18-year period by using quality-controlled and mostly accredited methods. 
The data are intact in the sense that no preselection of cases has occurred according to the cause of 
death or any criterion other than the number of qualified findings per drug. Hence, there is no prior 
interpretation by a pathologist or toxicologist that might create a bias. The reader should use the data 
in case work with consideration and taking into account all of the necessary circumstantial and 
contributory factors related to the case. The strength of the present all-causes-of-death approach is 
that it provides abundant data for a statistically reliable basis for ‘normal’ PM drug concentrations in 
blood and even offers potential for answering the question ‘was it a poisoning?’ – but only in the right 
context. 
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Table 1. Demographics and mean blood alcohol concentration for autopsy cases with comprehensive post-mortem drug analysis completed. 
 
Sex N Age, years 
Mean (median) highest 
Na Blood ethanol, ‰ (g/kg) 
Mean (median) highest 
Male 90,398 (74%) 56.5 (58) 103 35,889 (81%) 1.71 (1.60) 7.7 
Female 31,836 (26%) 61.9 (64) 105 8,243 (19%) 1.64 (1.50) 8.5 
Both sexes 122,234 (100%) 57.9 (59) 105 44,132 (100%) 1.70 (1.60) 8.5 
aBlood ethanol ≥ 0.2‰ 
Table 2. Descriptive statistics for concentrations of drugs determined in post-mortem (PM) femoral blood representing all causes of death. 
 
Drug PM 
cases 
PM LOQ PM mean  PM 
median 
Upper PM percentiles mg/L Therapeutic 
concentration in 
plasma (Cplasma)a 
Previous 
PM 
medianb 
Difference in PM 
median from 
previous datac 
 N mg/L mg/L mg/L 90th 95th 97.5th mg/L mg/L % 
Acebutolol 115 0.25 11 0.77 23 72 100 2 0.84 -8 
Alfentanil 119 0.00005 0.029 0.016 0.08 0.10 0.16 0.60 
 
 
Alprazolam 2234 0.02 0.06 0.033 0.12 0.20 0.33 0.05 0.05 -34 
Alprazolam, 1-hydroxy- 821 0.001 0.005 0.002 0.010 0.018 0.028 0.00339 
 
 
Aminophenazone, 4-methyl- 599 2/3d 21 12 50 67 96 10e 15 -20 
Amiodarone 137 0.4 3.9 1.8 8.0 11 18 2 1.8 0 
Amitriptyline 2604 0.1 1.3 0.40 2.6 4.6 7.9 0.30 0.40 0 
Amitriptyline, N-desmethyl- 1347 0.1 0.59 0.30 1.3 2.0 3.0 0.2540 
 
 
Amlodipine 3081 0.006 0.09 0.055 0.16 0.21 0.28 0.015 0.07 -21 
Amphetamine 1087 0.04 0.80 0.26 1.9 2.9 4.4 0.10 0.28 -7 
Aripiprazole 199 0.1 0.29 0.15 0.51 0.71 0.86 0.50 
 
 
Atenolol 668 0.2 1.5 0.69 2.6 4.3 6.1 1.0 0.64 9 
Betaxolol 156 0.003 0.20 0.10 0.31 0.40 0.43 0.05 0.10 0 
Biperiden 38 0.1 0.20 0.10 0.30 0.32 0.46 0.10 0.10 0 
Bisoprolol 7570 0.01 0.11 0.05 0.18 0.28 0.45 0.10 0.05 0 
Bupivacaine 99 0.2/0.05d 1.5 0.36 1.3 3.3 4.7 1.5 0.40 -10 
Buprenorphine 1549 0.0002 0.0033 0.0013 0.0059 0.0095 0.019 0.015 0.0012 8 
Buprenorphine, nor- 1251 0.0002 0.0038 0.0012 0.0078 0.014 0.025 0.00541 
 
 
Bupropion 204 0.1 3.7 0.28 7.2 17 42 0.10 
 
 
Buspirone 27 0.05 0.083 0.050 0.23 0.30 0.33 0.0142 
 
 
Caffeine 32721 1/3d 4.7 3.9 8.5 11 14 10 3.0 30 
Candesartan 291 0.005 0.12 0.03 0.20 0.40 0.64 0.18 
 
 
Carbamazepine 2228 1/0.3d 7.6 6.3 13 18 26 8.0 6.2 2 
Carbamazepine, 10,11-dihydro-10-hydroxy- 834 5/3d 27 22 50 62 80 35 22 0 
Carvedilol 253 0.003 0.040 0.018 0.080 0.13 0.30 0.15 0.02 -10 
Celiprolol 177 0.03 3.3 0.27 2.7 5.3 8.7 0.50 0.28 -4 
Cetirizine 112 0.001 0.67 0.11 0.90 1.9 3.0 0.30 0.10 10 
Chlordiazepoxide 2408 0.2 1.4 0.61 3.0 4.8 6.9 3.0 0.70 -13 
Chloroquine 59 0.2 10 0.67 39 55 67 0.50 1.3 -48 
Chlorpromazine 291 0.05 0.95 0.30 2.1 3.9 6.5 0.10 0.30 0 
Chlorprothixene 755 0.1 1.8 0.30 2.6 5.0 9.0 0.30 0.30 0 
Citalopram 5800 0.1 0.87 0.40 1.3 2.1 4.5 0.40 0.40 0 
Citalopram, N-desmethyl- 892 0.5/0.05d 0.39 0.21 0.83 1.1 1.7 0.1543 
 
 
Clobazam 42 0.1/0.05d 0.35 0.20 0.71 1.3 1.6 0.6144 
 
 
Clobazam, N-desmethyl- 101 0.2/0.05d 1.6 0.90 3.4 5.5 8.6 1.545 
 
 
Clobutinol 23 0.2/0.05d 0.54 0.30 0.87 1.4 2.1 0.20 
 
 
Clomipramine 155 0.1 1.0 0.60 2.2 3.4 4.0 0.40 
 
 
Clomipramine, N-desmethyl- 81 0.5/0.05d 2.7 1.2 4.8 7.1 20 1.046 
 
 
Clonazepam 315 0.01 0.030 0.011 0.041 0.080 0.10 0.08 0.03 -63 
Clonazepam, 7-amino- 1790 0.005 0.17 0.094 0.38 0.56 0.83 0.1447 
 
 
Clozapine 880 0.1 2.7 1.1 4.3 8.7 16 0.60 1.1 0 
Codeine 3633 0.02 0.65 0.14 1.4 2.7 4.6 0.25 0.16 -13 
Cyclizine 62 0.005 1.1 0.30 1.2 2.3 5.9 0.25 0.30 0 
Demoxepam 727 0.1 1.1 0.80 2.5 3.1 4.0 2.848 
 
 
Desloratadine 56 0.001 0.071 0.031 0.13 0.24 0.44 0.006 
 
 
Dextromethorphan 91 0.1 0.57 0.30 1.5 1.9 2.5 0.04 0.40 -25 
Dextropropoxyphene 270 0.1 6.6 2.6 12 18 41 0.30 2.6 0 
Diazepam 11831 0.02 0.17 0.090 0.40 0.60 0.80 2.0 0.09 0 
Diazepam, N-desmethyl- 15945 0.02 0.21 0.10 0.50 0.70 0.99 0.80 0.10 0 
Diclofenac 69 0.5/0.3d 2.2 1.1 5.6 6.9 8.3 3.0 1.3 -15 
Digoxin 2578 0.0005 0.0028 0.0018 0.0045 0.0063 0.0086 0.002 
 
 
Diltiazem 422 0.1 2.4 0.30 1.8 7.8 22 0.13 0.30 0 
Diphenhydramine 122 0.005 0.36 0.20 0.80 0.90 1.3 0.10 0.20 0 
Dixyrazine 57 0.003 0.79 0.10 1.9 5.7 6.9 0.30 0.10 0 
Donepezil 560 0.003 0.23 0.20 0.40 0.49 0.59 0.075 0.20 0 
Doxepin 902 0.05 2.2 0.60 6.3 10 15 0.20 0.60 0 
Doxepin, N-desmethyl- 254 0.2/0.05d 0.73 0.40 1.6 2.3 3.2 0.20 
 
 
Duloxetine 320 0.01 0.40 0.15 0.63 1.2 2.7 0.12 0.14 7 
Enalapril 115 0.01 0.10 0.032 0.16 0.47 0.66 0.10 
 
 
Ephedrine 357 0.04 0.50 0.20 0.90 1.5 2.3 0.20 0.21 -5 
Ethylmorphine 116 0.02 0.42 0.10 1.2 2.7 2.9 0.60 0.10 0 
Etoricoxib 141 0.5 2.9 1.5 5.0 6.3 8.6 3.6 1.2 25 
Felodipine 141 0.001 0.017 0.0020 0.040 0.060 0.15 0.012 
 
 
Fentanyl 1074 0.0001 0.010 0.0042 0.019 0.030 0.047 0.01 0.0058 -28 
Flecainide 166 0.2 4.1 1.8 8.7 16 23 0.80 1.9 -3 
Fluconazole 443 0.1 7.8 4.3 20 29 37 5.0 3.8 13 
Fluoxetine 868 0.2 0.84 0.50 1.9 2.8 3.7 0.50 0.50 0 
Flupentixol 43 0.001 0.020 0.0070 0.056 0.087 0.099 0.01 
 
 
Fluvoxamine 96 0.03 2.4 0.70 7.3 8.4 19 0.23 0.70 0 
Furosemide 310 0.1 2.5 0.90 5.5 9.1 16 5.0 0.90 0 
Gabapentin 541 1 27 12 58 93 145 6.0 11 9 
Galantamine 88 0.01 0.22 0.14 0.40 0.54 0.76 0.06 0.11 27 
Glibenclamide 45 0.08 0.28 0.09 0.31 0.63 0.69 0.20 
 
 
Glimepiride 211 0.01 0.27 0.03 0.21 0.38 1.0 0.50 0.03 0 
Haloperidol 335 0.003 0.02 0.009 0.03 0.046 0.12 0.017 0.01 -10 
Hydrochlorothiazide 581 0.05 0.34 0.23 0.69 0.99 1.3 2.0 
 
 
Hydroxychloroquine 394 1 12 8.0 26 33 45 0.10 10 -20 
Hydroxyzine 434 0.2 0.61 0.30 1.1 2.0 3.1 0.10 0.30 0 
Ibuprofen 1973 10 18 14 35 49 70 30 19 -26 
Indomethacin 51 0.5 1.3 1.0 2.1 3.0 3.9 1.0 1.1 -9 
Ketamine 358 0.1 0.82 0.44 1.5 2.4 4.1 6.0 0.50 -12 
Ketoprofen 249 0.3 3.3 1.2 5.7 10 21 3.7 1.3 -8 
Labetalol 216 0.01 0.12 0.059 0.25 0.35 0.42 0.18 0.09 -34 
Lacosamide 57 1 8.9 6.0 16 23 27 10 
 
 
Lamotrigine 691 1/0.5d 4.9 3.0 10 15 24 14 3.8 -21 
Levetiracetam 457 3 28 18 61 78 90 40 15 20 
Levomepromazine 2274 0.1 1.1 0.31 1.9 3.2 5.1 0.025 0.40 -23 
Lidocaine 3853 0.1 0.75 0.34 1.7 2.5 3.9 5.0 0.40 -15 
Lithium 223 0.5 3.9 2.5 7.5 11 19 8.0 2.0 25 
Lorazepam 1676 0.01 0.04 0.02 0.07 0.10 0.20 0.25 0.03 -33 
Losartan 720 0.005 0.13 0.03 0.27 0.48 0.80 0.65 
 
 
Losartan, carboxylic acid (EXP3174) 602 0.005 0.12 0.05 0.26 0.52 0.79 0.6049 
 
 
MDA 47 0.05 0.13 0.07 0.19 0.45 1.0    
MDMA 139 0.04 1.1 0.49 3.0 3.7 5.0 0.35 0.30 63 
Meloxicam 40 0.2 2.2 1.4 5.5 9.0 9.1 2.00 
 
 
Melperone 174 0.05 1.6 0.40 3.4 9.4 16 0.10 0.40 0 
Memantine 302 0.02 0.74 0.48 1.6 2.0 2.4 0.15 
 
 
Meprobamate 194 10 18 3.3 52 72 83 10 28 -88 
Mesoridazine 88 0.2 0.74 0.50 1.2 1.6 2.6 1.0 0.50 0 
Metformin 3386 1 14 5.1 34 61 92 1.0 6.0 -15 
Methadone 466 0.05 0.63 0.50 1.4 1.7 2.0 0.50 0.40 25 
Methamphetamine 185 0.04 0.86 0.18 1.2 2.1 2.8 0.10 0.18 0 
Methylphenidate 30 0.05/0.1d 0.20 0.10 0.28 0.38 0.83 0.06 
 
 
Metoclopramide 1209 0.05 0.21 0.10 0.40 0.60 0.80 0.15 0.10 0 
Metoprolol 3681 0.05 0.90 0.20 1.1 1.9 4.0 0.50 0.20 0 
Mianserin 487 0.05 0.37 0.20 0.70 1.1 2.0 0.1340 0.20 0 
Mianserin, N-desmethyl- 130 0.1 0.47 0.30 0.80 1.1 1.5 0.0850 
 
 
Midazolam 445 0.02 0.12 0.046 0.24 0.46 0.60 0.10 0.07 -34 
Midazolam, 1-hydroxy- 621 0.002 0.053 0.008 0.10 0.18 0.30 0.4051 
 
 
Mirtazapine 3820 0.05 0.45 0.19 0.70 1.5 2.7 0.08 0.20 -5 
Moclobemide 177 0.1 14 1.9 36 49 120 1.0 1.9 0 
Morphine 2134 0.02 0.21 0.070 0.35 0.61 0.95 0.10 0.07 0 
Naloxone 167 0.0006 0.0082 0.0020 0.013 0.023 0.033 0.03 
 
 
Naproxen 847 10 33 23 66 89 110 50 33 -30 
Nifedipine 74 0.02 0.20 0.067 0.29 0.53 0.73 0.15 0.10 -33 
Nitrazepam 86 0.05 0.080 0.034 0.20 0.30 0.49 0.10 0.06 -43 
Olanzapine 2215 0.05 0.45 0.20 0.80 1.4 2.4 0.08 0.20 0 
Orphenadrine 551 0.1 0.94 0.34 1.8 3.3 5.9 0.20 0.30 13 
Oxazepam 9467 0.02 0.28 0.072 0.69 1.2 1.9 1.5 0.07 3 
Oxcarbazepine 269 0.3 1.6 0.70 3.4 5.6 8.6 2.0 0.60 17 
Oxycodone 3114 0.02 0.29 0.08 0.45 0.80 1.5 0.10 0.10 -20 
Paliperidone (9-hydroxyrisperidone) 193 0.002 0.021 0.013 0.040 0.060 0.10 0.0627 
 
 
Paracetamol 9579 5/10d 36 18 67 120 200 25 15 20 
Paroxetine 482 0.004 0.69 0.24 1.2 2.0 3.4 0.05 0.24 0 
Pentobarbital 38 0.5 7.3 2.5 26 27 30 5.0 
 
 
Perphenazine 477 0.005 0.070 0.010 0.070 0.17 0.36 0.02 0.01 0 
Pethidine 59 0.1 0.52 0.30 1.1 1.3 1.8 0.80 0.30 0 
Phenazepam 116 0.03 0.090 0.050 0.21 0.29 0.38 0.04 0.09 -45 
Phenobarbital 46 10 20 16 45 53 55 30 30 -47 
Phenylpropanolamine 156 0.04 0.31 0.12 0.55 1.1 1.4 0.50 0.14 -14 
Phenytoin 355 10 8.6 7.8 16 20 25 15 13 -40 
Pholcodine 84 0.02 0.37 0.17 0.82 1.1 1.6 0.20 0.19 -11 
Pioglitazone 86 0.01 0.15 0.080 0.36 0.49 0.55 2.052 
 
 
Pregabalin 1619 0.2 18 8.8 39 60 91 8.3 8.0 10 
Prilocaine 38 0.1/0.05d 0.79 0.30 1.6 2.0 3.3 2.0 
 
 
Promazine 371 0.1 4.2 1.0 11 18 26 0.05 1.2 -17 
Propofol 786 0.1/0.5d 2.5 1.3 5.6 8.2 11 8.0 1.3 0 
Propranolol 1805 0.02 1.5 0.13 4.7 8.5 14 0.30 0.13 0 
Pseudoephedrine 254 0.04 0.71 0.26 1.5 2.4 4.1 0.80 0.24 8 
Quetiapine 1792 0.2 3.5 0.51 6.4 13 25 0.50 0.90 -43 
Quinine 495 0.2 2.9 0.80 3.8 10 29 7.0 1.0 -20 
Risperidone 973 0.002 0.010 0.004 0.021 0.040 0.070 0.006 0.004 0 
Rivastigmine 79 0.003 0.030 0.010 0.051 0.090 0.13 0.02 0.01 0 
Ropivacaine 118 0.1 2.0 0.70 2.8 3.8 6.6 1.5 0.70 0 
Rosiglitazone 18 0.05 0.14 0.070 0.23 0.54 0.77 0.30 
 
 
Salicylic acid 1716 5/3d 37 9.4 60 110 310 200 11 -15 
Sertraline 760 0.1 0.54 0.30 1.0 1.6 2.3 0.25 0.30 0 
Sildenafil 135 0.03 0.27 0.13 0.40 0.53 0.72 0.50 0.10 30 
Sitagliptin 1339 0.01 0.65 0.40 1.4 2.0 2.9 0.38 0.36 11 
Sotalol 169 0.25 3.0 2.0 5.8 9.0 13 3.0 2.0 0 
Sulpiride 142 0.02 4.0 0.80 8.3 20 32 0.40 1.1 -27 
Sumatriptan 32 0.01 1.4 0.28 2.4 5.2 11 0.06 
 
 
Telmisartan 93 0.005 0.41 0.19 1.0 1.4 3.0 4.053 
 
 
Temazepam 9545 0.02 0.35 0.09 0.88 1.5 2.4 0.15 0.09 0 
Tetrahydrocannabinol 884 0.001 0.010 0.0024 0.0092 0.016 0.029 0.01 0.002 20 
THC, 11-hydroxy- 60 0.003 0.015 0.006 0.020 0.030 0.050 
  
 
THC-COOH (11-nor-9-carboxy-THC) 310 0.003 0.030 0.018 0.070 0.10 0.14 
  
 
Theobromine 56 2 11 9.8 19 24 29 15 
 
 
Theophylline 388 10 16 11 24 45 84 15 15 -27 
Thiopental 27 1 9.4 5.0 15 22 38 5.0 
 
 
Thioridazine 299 0.1 1.3 0.70 3.0 4.3 6.3 2.0 0.70 0 
Tizanidine 214 0.003 0.14 0.026 0.21 0.45 0.93 0.015 0.02 30 
Topiramate 137 1/3d 16 10 24 33 47 10 8.8 14 
Tramadol 2636 0.1 3.4 0.91 7.1 14 22 1.0 0.90 1 
Tramadol, N-desmethyl- 843 0.2/0.1d 1.1 0.42 2.3 4.1 6.0 0.3054,55 
 
 
Tramadol, O-desmethyl- 951 0.2/0.1d 0.78 0.40 1.7 2.4 3.8 0.3054,55 
 
 
Trazodone 115 0.2 1.9 0.48 4.3 7.5 15 1.0 0.40 20 
Trimethoprim 738 1 3.4 2.2 6.5 9.0 12 2.5 2.3 -4 
Trimipramine 319 0.1 1.1 0.60 2.4 3.4 5.0 0.30 0.60 0 
Trimipramine, N-desmethyl- 93 0.1/0.05d 0.98 0.60 2.3 3.2 3.6 0.4056 
 
 
Valproic acid 1859 1/3d 50 30 75 99 193 100 28 7 
Valsartan 103 0.005 1.5 0.36 4.2 5.8 13 6.0 
 
 
Venlafaxine 1609 0.1 4.1 0.60 5.4 16 36 0.40 0.70 0 
Warfarin 2373 0.5 0.64 0.57 1.0 1.3 1.8 3.0 0.60 -19 
Venlafaxine, N-desmethyl- 36 0.05 0.47 0.40 0.96 1.3 1.4 0.5057 
 
 
Venlafaxine, O-desmethyl- 362 0.1 0.85 0.47 1.6 2.6 3.8 0.5057 
 
 
Verapamil 249 0.1 2.2 0.40 5.8 11 13 0.25 0.35 14 
Vildagliptin 38 0.05 0.11 0.059 0.27 0.38 0.40 1.658 
 
 
Vortioxetine 43 0.003 0.14 0.090 0.17 0.29 0.47 0.0759 
 
 
Xylometazoline 23 0.05 0.008 0.001 0.004 0.011 0.070 
  
 
Zolpidem 557 0.1 0.64 0.29 1.3 1.9 3.4 0.15 0.30 -3 
Zopiclone 5778 0.02 0.33 0.08 0.66 1.3 2.5 0.05 0.10 -20 
Zuclopenthixol 274 0.005 0.10 0.05 0.20 0.35 0.51 0.05 0.05 0 
 
  
aUpper limit of established therapeutic concentration in plasma (Cplasma) derived from Schulz et al. (ref. 21) unless another reference indicated as superscript 
bPM median concentration from previously published data by Launiainen and Ojanperä (ref. 14) 
cDifference in PM median concentration between current data and previously published data by Launiainen and Ojanperä (ref. 14) 
dData combined from two successive methods; validation parameters presented in order of appearance 
eFor parent drug metamizole 
 
